A recently launched cannabis exchange-traded fund (ETF) focused on the US has added a C$1 billion company to its list of holdings.

On Monday (May 13), Columbia Care (NEO:CCHWwas included in the Horizons US Marijuana Index ETF (NEO:HMUS), run by Horizons ETFs Management (Canada).

The medical marijuana company made its debut on the NEO Exchange in April, becoming the first company with an enterprise value of over C$1 billion to list on the exchange thanks to a merger with a special purpose acquisition corporation (SPAC).

According to Horizons ETFs, Columbia Care’s C$2 billion valuation makes the company eligible for a maximum weighting of 10 percent in the fund’s portfolio.

Normally, the Horizons US Marijuana Index ETF adds new stocks during a quarterly rebalancing done by Horizons ETFs. However, this addition was done via a “fast entry” rule.

The ETF launched in April, and Steve Hawkins, president and CEO of Horizons ETFs, said in a press release that he anticipates seeing investors gain interest in the US market as the country undergoes regulation changes for cannabis.

As of the Friday (May 10) trading session, Columbia Care was the fourth largest holding for the fund, coming behind Cresco Labs (CSE:CL,OTCQX:CRLBF), Charlotte’s Web (CSE:CWEB,OTCQX:CWBHF) and Curaleaf Holdings (CSE:CURA,OTCQX:CURLF).

Marijuana remains an illegal substance at a federal level in the US, despite legalization programs from several states opening the market to medical or recreational sales.

Columbia Care’s roadmap to its public debut

According to Nicholas Vita, vice chairman and CEO of Columbia Care, the firm is focused on solving “some of the world’s most challenging unmet medical and health needs through the use of our proprietary portfolio of consistently dosed, pharmaceutical-quality cannabis-based medicines.”

Columbia Care reached the NEO Exchange after completing a merger with a public entity created by financial institution Canaccord Genuity (TSX:CF,OTC Pink:CCORF) and designed as a SPAC.

“In this particular case we sold C$40 million of effective blind pool cash into a public vehicle and then we said look, if someone wants to go public they can just merge with our SPAC,” Canaccord’s president and CEO, Dan Daviau, told the Financial Post.

During its Q1 financial results release last Wednesday (May 8), Columbia Care posted revenues of US$12.9 million. The company earned US$39.3 million in revenue during 2018.

Vita said that thanks to its public debut, the company will be able to accelerate its roadmap of operations in the US.

The executive added that the public launch will also aid in the launch of the company’s hemp-derived cannabidiol products into “traditional consumer retail channels.”

SPAC debuts in the cannabis market gain momentum

During the Vancouver edition of the Arcview Investor Forum in April, Jonathan Sandelman, CEO of Cannabis Strategies Acquisition (NEO:CSA.A), said that SPACs are very transparent, which will be a big attraction point for investors.

“Its mission is to be very much like a private equity firm, but with daily liquidity, with the optionality not given to a private equity manager but to the investor,” Sandelman said.

The SPAC executive said his firm has already acquired five marijuana companies in the US.

On Monday, Mercer Park Brand Acquisition (NEO:BRND.U) started trading, adding another cannabis SPAC company to the NEO Exchange’s listings.

The firm raised US$402 million as part of its initial public offering. According to the NEO Exchange, Mercer Park will focus on acquiring companies with a value between US$300 million and US$800 million.

Anna Serin, director of listings development with the Canadian Securities Exchange, told the audience at the Arcview Investor Forum the exchange is getting ready to begin offering SPACs amongst its cannabis listings in the near future.

“With a SPAC, you’re investing in a management team who’s going to go out and acquire assets … in the future,” she said.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less